Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside

Human    T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement

(2010) A. Maniar et al.   BLOOD

The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to    T-cell cytotoxicity

(2010) T. Lanca et al.   BLOOD

Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients

(2010) Florian Cabillic et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood    T cells

(2010) A. Q. Gomes et al.   HAEMATOLOGICA

F1-Adenosine Triphosphatase Displays Properties Characteristic of an Antigen Presentation Molecule for V 9V 2 T Cells

(2010) J. Mookerjee-Basu et al.   JOURNAL OF IMMUNOLOGY

V 9V 2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells

(2010) M. D'Asaro et al.   JOURNAL OF IMMUNOLOGY

Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine

(2010) A E Foster et al.   LEUKEMIA

B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells

(2010) E Gross et al.   LEUKEMIA

Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management

(2010) T D Shanafelt et al.   LEUKEMIA

An six-amino acid motif in the α3 domain of MICA is the cancer therapeutic target to inhibit shedding

(2009) Xuanjun Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

(2009) J. Gertner-Dardenne et al.   BLOOD

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

(2009) Michele Moschetta et al.   EUROPEAN JOURNAL OF CANCER

Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

(2009) Yu Abe et al.   EXPERIMENTAL HEMATOLOGY

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway

(2009) Marta Coscia et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by V 9V 2 T Cells

(2009) J. Li et al.   JOURNAL OF IMMUNOLOGY

Efficient Killing of Human Colon Cancer Stem Cells by    T Lymphocytes

(2009) M. Todaro et al.   JOURNAL OF IMMUNOLOGY

Phosphoantigen‐Expanded Human γδ T Cells Display Potent Cytotoxicity against Monocyte‐Derived Macrophages Infected with Human and Avian Influenza Viruses

(2009) Gang Qin et al.   JOURNAL OF INFECTIOUS DISEASES

Natural killer and γδ T cells in haematological malignancies: enhancing the immune effectors

(2009) Jérôme Rey et al.   TRENDS IN MOLECULAR MEDICINE

Phosphoantigen-activated V 2V 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection

(2008) G. Gong et al.   BLOOD

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

(2008) A. Soriani et al.   BLOOD

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16

(2008) Christophe de Romeuf et al.   BRITISH JOURNAL OF HAEMATOLOGY

Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP

(2008) Anke J. Roelofs et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

(2008) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

(2008) W. Matsui et al.   CANCER RESEARCH

Activation of cytotoxic T-cell receptor    T lymphocytes in response to specific stimulation in myelodysplastic syndromes

(2008) J.-J. Kiladjian et al.   HAEMATOLOGICA

Inhibition of phosphoantigen-mediated γδ T-cell proliferation by CD4+ CD25+ FoxP3+regulatory T cells

(2008) Volker Kunzmann et al.   IMMUNOLOGY

Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab

(2008) Hirotake Tokuyama et al.   INTERNATIONAL JOURNAL OF CANCER